PAHC vs. KRYS, RYTM, CYTK, PTCT, ZLAB, ACAD, MRUS, ACLX, SWTX, and RNA
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.
Phibro Animal Health vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.
In the previous week, Krystal Biotech had 12 more articles in the media than Phibro Animal Health. MarketBeat recorded 17 mentions for Krystal Biotech and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.23 beat Krystal Biotech's score of 0.11 indicating that Phibro Animal Health is being referred to more favorably in the media.
Krystal Biotech has lower revenue, but higher earnings than Phibro Animal Health. Krystal Biotech is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.
Phibro Animal Health currently has a consensus price target of $21.80, suggesting a potential downside of 22.12%. Krystal Biotech has a consensus price target of $211.13, suggesting a potential upside of 47.63%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Phibro Animal Health.
Krystal Biotech has a net margin of 37.17% compared to Phibro Animal Health's net margin of 2.68%. Phibro Animal Health's return on equity of 30.51% beat Krystal Biotech's return on equity.
99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 13.7% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Krystal Biotech beats Phibro Animal Health on 10 of the 17 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:PAHC) was last updated on 7/5/2025 by MarketBeat.com Staff
